Abstract :
Abstract The use of stereotactic ablative radiotherapy (SABR) or stereotactic body radiation therapy (SBRT) is expanding beyond its initial focus on treating tumours in the liver and lungs due to the remarkable success in controlling these malignancies. While technological advancements have been crucial to SBRT's success, biological constraints are currently limiting the use of highly effective SBRT regimens. Although SBRT will keep becoming more popular, there are still some questions about how normal tissues and tumours react to high dose per fraction radiation. This will help us understand how to improve the technology and prevent damage from being caused by too strong SBRT treatments. The models used to estimate biological consequences at high dose per fraction are undergoing a paradigm shift in radiobiology, even if the underlying mechanisms are still not fully understood. Additionally, SBRT may provide scheduling benefits that could be taken advantage of. Due to their serious adverse effects, radioprotective or hypoxic cell cytotoxic medicines that were either discontinued or were not utilised actively should be reevaluated. There is a mechanistic explanation that suggests SBRT is not suitable for tumours with low oxygen levels, therefore this may be particularly true in hypoxia. That idea, though, would be challenged by us.
Keyword :
Keywords: Radiobiology, Therapy/Stereotactic Ablative Radiotherapy, Risk Factor, Normal Tissue Response